Lurasidone: The most recent addition to our antipsychotic armamentarium

Psychopharm Review

Volumn 46, Issue 6, 2011, Pages 41-47

  Fayad, Sarah M ^a   Tandon, Rajiv ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR; CYTOCHROME P450 3A4; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HALOPERIDOL; HISTAMINE H1 RECEPTOR; HISTAMINE H1 RECEPTOR ANTAGONIST; INSULIN; KETOCONAZOLE; LURASIDONE; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RIFAMPICIN; SEROTONIN 1A AGONIST; SEROTONIN 2A ANTAGONIST; SEROTONIN 2C AGONIST; SEROTONIN 2C ANTAGONIST; SEROTONIN 7 RECEPTOR ANTAGONIST; SEROTONIN ANTAGONIST; UNCLASSIFIED DRUG; ZIPRASIDONE;

AGITATION; AKATHISIA; ANXIETY; ATTENTION DISTURBANCE; BIPOLAR I DISORDER; BLOOD PRESSURE; BLURRED VISION; BODY TEMPERATURE DISORDER; CEREBROVASCULAR DISEASE; COGNITIVE DEFECT; CONSTIPATION; DEMENTIA RELATED PSYCHOSIS; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSLIPIDEMIA; DYSPHAGIA; DYSPHORIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; GALACTORRHEA; GERIATRIC PATIENT; GYNECOMASTIA; HUMAN; HYPERALGESIA; HYPERGLYCEMIA; HYPERPROLACTINEMIA; INSULIN SENSITIVITY; LEUKOPENIA; LIVER METABOLISM; MENSTRUAL CYCLE; MONOTHERAPY; MORTALITY; NEGATIVE SYNDROME; NEUROLEPTIC MALIGNANT SYNDROME; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PHARMACODYNAMICS; PROLACTIN BLOOD LEVEL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; SEDATION; SEIZURE; SEXUAL DYSFUNCTION; SHORT COURSE THERAPY; SIDE EFFECT; SINUS TACHYCARDIA; SMOKING; SOMNOLENCE; STEADY STATE; TARDIVE DYSKINESIA; TREATMENT CONTRAINDICATION; TRIACYLGLYCEROL BLOOD LEVEL; URINE RETENTION; WEIGHT GAIN; XEROSTOMIA;

EID: 80052848959     PISSN: 19369255     EISSN: None     Source Type: Trade Journal    
DOI: 10.1097/01.PSYPHR.0000397993.50008.5c     Document Type: Review

References (13)

1. Tandon R, Belmaker RH, Gattaz WF, et al. World Psychiatry Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res. 2008;100(1-3):20-38.
2. Buchanan RW, Kreyenbuhl J, Kelly DL, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010;36(1):71-93.
3. Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, "Just the facts" 5. Treatment and prevention. Schizophr Res. 2010;122(1-3):1-23.
4. Kapur S, Remington G. Dopamine D2 receptors and their role in antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry. 2001;50(11): 873-883. (Pubitemid 34020700)
5. Chen H, Tandon R. First- and second-generation antipsychotics and the concept of "atypicality": implications for clinical practice. Psychopharm Rev. 2009;44(11):81-88.
6. Castagne V, Moser PC, Porsolt RD. Preclinical behavioral models for predicting antipsychotic activity. Adv Pharmacol. 2009;57:381-418.
7. Meyer JM, Loebel AD, Schweizer E. Lurasidone: a new drug in development for schizophrenia. Expert Opin Investig Drugs. 2009;18(11):1715-1726.
8. Nakamura M, Ogasa M, Guarino J, et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70(6): 829-836.
9. Citrome L. Systematic review. Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic. Int J Clin Pract. 2011;65(2):189-210.
10. Harvey PD, Ogasa M, Cucchiaro J, et al. Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone versus ziprasidone. Schizophr Res. 2011;127(1-3):188-194.
11. Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, "Just the facts" 4. Clinical features and conceptualization. Schizophr Res. 2009;110(1-3):1-23.
12. Keefe RSE, Bilder RM, Davis SM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry. 2007;64(6):633-647. (Pubitemid 46878665)
13. Fischer-Barnicol D, Lanquillon S, Haen E, et al. Typical and atypical antipsychotics-the misleading dichotomy. Results from the working group "Drugs in Psychiatry" (AGATE). Neuropsychobiology. 2008;57(1-2): 80-87. (Pubitemid 351859338)